Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...

The rules are a game-changer that supporters say will require companies to be more transparent and take the burden off regulators in trying to prevent illegal mergers and acquisitions. Opponents argue ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...

Sanofi agrees to sell a 50% stake in Opella to CDR for €15bn, securing job promises. Discover the impact on France ...

French drugmaker Sanofi's Monday confirmation that it plans to sell a controlling stake in its over-the-counter unit to a US investment fund sparked a new political backlash, stoked by fears the deal ...

In a report released today, Peter Welford from Jefferies maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target ...

French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to ...

Sanofi and CD&R have entered exclusive negotiations for CD&R to acquire a 50% controlling stake in Opella, Sanofi’s consumer ...

Highlights,France is poised to acquire a 2% stake in Sanofi SA's consumer healthcare unit, Opella, as part of a €16 billion ...

Sanofi announced on Monday that it had entered into exclusive negotiations with US investment fund CD&R to sell it a majority ...

Sanofi and CD&R announce today a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer ...